Bio-Techne
Bio-Techne Corporation, a leading player in the biotechnology sector, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 1976, the company has established itself as a pioneer in providing high-quality reagents, instruments, and services for life sciences research and clinical diagnostics. Bio-Techne's core offerings include proteins, antibodies, and assay kits, which are distinguished by their exceptional quality and reliability. The company is renowned for its innovative solutions that support advancements in genomics, proteomics, and cell biology. With a strong market position, Bio-Techne has achieved notable milestones, including strategic acquisitions that have expanded its product portfolio and global reach, solidifying its reputation as a trusted partner in scientific research and development.
DitchCarbon Score
How does Bio-Techne's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bio-Techne's score of 41 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bio-Techne's reported carbon emissions
In 2023, Bio-Techne reported total carbon emissions of approximately 17,565,000 kg CO2e, with Scope 1 emissions at about 2,982,000 kg CO2e and Scope 2 emissions at around 14,583,000 kg CO2e. This represents an increase from 2022, when total emissions were about 15,600,000 kg CO2e, with Scope 1 at 3,000,000 kg CO2e and Scope 2 at 12,600,000 kg CO2e. In 2021, the company recorded total emissions of approximately 13,628,000 kg CO2e, with Scope 1 emissions of about 3,338,000 kg CO2e and Scope 2 emissions of around 10,290,000 kg CO2e. Bio-Techne has committed to reducing its greenhouse gas emissions across all scopes (1, 2, and 3) and has submitted a letter of commitment to the Science Based Targets Initiative (SBTi) for validation in 2026. This commitment is part of their near-term strategy to achieve significant reductions in emissions, although specific percentage targets have not been disclosed. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector and is headquartered in the United States. As of now, there are no reported Scope 3 emissions, and the company has not yet established long-term net-zero targets.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 3,338,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 10,290,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bio-Techne is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
